Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use

Background: We evaluated feasibility, safety, and total resource use of subcutaneous immunoglobulin (SCIG) in a pilot study of patients who underwent allogeneic hematopoietic cell transplant (HCT) over a 6-month period. Methods: A total of 20 eligible patients were treated with SCIG at 0.1 g/kg/week...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ivan Pasic, Wael Alanazi, George Dranitsaris, Lani Lieberman, Auro Viswabandya, Dennis Dong Hwan Kim, Jeffrey H. Lipton, Fotios V. Michelis
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Allogeneic hematopoietic cell transplant Feasibility Hypogammaglobulinemia Pilot study Subcutaneous immunoglobulin Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e6b8adf073bc4e35abc6c80347e3c072
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e6b8adf073bc4e35abc6c80347e3c072
record_format	dspace
spelling	oai:doaj.org-article:e6b8adf073bc4e35abc6c80347e3c0722021-12-02T05:00:01ZSubcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use1658-387610.1016/j.hemonc.2021.01.001https://doaj.org/article/e6b8adf073bc4e35abc6c80347e3c0722021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1658387621000017https://doaj.org/toc/1658-3876Background: We evaluated feasibility, safety, and total resource use of subcutaneous immunoglobulin (SCIG) in a pilot study of patients who underwent allogeneic hematopoietic cell transplant (HCT) over a 6-month period. Methods: A total of 20 eligible patients were treated with SCIG at 0.1 g/kg/week for up to 6 months. Patients were matched to 20 concurrent intravenous immunoglobulin (IVIG) controls. Clinical outcomes measured included adverse reactions, healthcare resource use, patient satisfaction, and quality of life (QOL). (ClinicalTrials.gov Identifier: NCT03401268.) Results: Groups were comparable in terms of age, weight, sex, transplant indication, donor type, and conditioning intensity. All 20 IVIG patients completed 6 consecutive months of therapy compared with 13/20 (65%) SCIG patients. There were no adverse reactions in IVIG patients, compared with six (30%) SCIG patients. All adverse reactions in SCIG patients were grade I, transient, and required no medical intervention. Median overall cost per patient was lower with SCIG than with IVIG ($9,756 vs. $13,780, p = .046). Among patients who completed 6 months of SCIG, median preference and satisfaction scores were 100%. Over the 6-month period, QOL scores remained stable in SCIG patients. Conclusions: In a subgroup of patients, SCIG was associated with high patient satisfaction and a reduction in total healthcare costs compared with IVIG in a cohort of HCT patients.Ivan PasicWael AlanaziGeorge DranitsarisLani LiebermanAuro ViswabandyaDennis Dong Hwan KimJeffrey H. LiptonFotios V. MichelisElsevierarticleAllogeneic hematopoietic cell transplantFeasibilityHypogammaglobulinemiaPilot studySubcutaneous immunoglobulinDiseases of the blood and blood-forming organsRC633-647.5Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENHematology/Oncology and Stem Cell Therapy, Vol 14, Iss 4, Pp 302-310 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Allogeneic hematopoietic cell transplant Feasibility Hypogammaglobulinemia Pilot study Subcutaneous immunoglobulin Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Allogeneic hematopoietic cell transplant Feasibility Hypogammaglobulinemia Pilot study Subcutaneous immunoglobulin Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ivan Pasic Wael Alanazi George Dranitsaris Lani Lieberman Auro Viswabandya Dennis Dong Hwan Kim Jeffrey H. Lipton Fotios V. Michelis Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use
description	Background: We evaluated feasibility, safety, and total resource use of subcutaneous immunoglobulin (SCIG) in a pilot study of patients who underwent allogeneic hematopoietic cell transplant (HCT) over a 6-month period. Methods: A total of 20 eligible patients were treated with SCIG at 0.1 g/kg/week for up to 6 months. Patients were matched to 20 concurrent intravenous immunoglobulin (IVIG) controls. Clinical outcomes measured included adverse reactions, healthcare resource use, patient satisfaction, and quality of life (QOL). (ClinicalTrials.gov Identifier: NCT03401268.) Results: Groups were comparable in terms of age, weight, sex, transplant indication, donor type, and conditioning intensity. All 20 IVIG patients completed 6 consecutive months of therapy compared with 13/20 (65%) SCIG patients. There were no adverse reactions in IVIG patients, compared with six (30%) SCIG patients. All adverse reactions in SCIG patients were grade I, transient, and required no medical intervention. Median overall cost per patient was lower with SCIG than with IVIG ($9,756 vs. $13,780, p = .046). Among patients who completed 6 months of SCIG, median preference and satisfaction scores were 100%. Over the 6-month period, QOL scores remained stable in SCIG patients. Conclusions: In a subgroup of patients, SCIG was associated with high patient satisfaction and a reduction in total healthcare costs compared with IVIG in a cohort of HCT patients.
format	article
author	Ivan Pasic Wael Alanazi George Dranitsaris Lani Lieberman Auro Viswabandya Dennis Dong Hwan Kim Jeffrey H. Lipton Fotios V. Michelis
author_facet	Ivan Pasic Wael Alanazi George Dranitsaris Lani Lieberman Auro Viswabandya Dennis Dong Hwan Kim Jeffrey H. Lipton Fotios V. Michelis
author_sort	Ivan Pasic
title	Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use
title_short	Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use
title_full	Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use
title_fullStr	Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use
title_full_unstemmed	Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use
title_sort	subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: a prospective study of feasibility, safety, and healthcare resource use
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/e6b8adf073bc4e35abc6c80347e3c072
work_keys_str_mv	AT ivanpasic subcutaneousimmunoglobulininallogeneichematopoieticcelltransplantpatientsaprospectivestudyoffeasibilitysafetyandhealthcareresourceuse AT waelalanazi subcutaneousimmunoglobulininallogeneichematopoieticcelltransplantpatientsaprospectivestudyoffeasibilitysafetyandhealthcareresourceuse AT georgedranitsaris subcutaneousimmunoglobulininallogeneichematopoieticcelltransplantpatientsaprospectivestudyoffeasibilitysafetyandhealthcareresourceuse AT lanilieberman subcutaneousimmunoglobulininallogeneichematopoieticcelltransplantpatientsaprospectivestudyoffeasibilitysafetyandhealthcareresourceuse AT auroviswabandya subcutaneousimmunoglobulininallogeneichematopoieticcelltransplantpatientsaprospectivestudyoffeasibilitysafetyandhealthcareresourceuse AT dennisdonghwankim subcutaneousimmunoglobulininallogeneichematopoieticcelltransplantpatientsaprospectivestudyoffeasibilitysafetyandhealthcareresourceuse AT jeffreyhlipton subcutaneousimmunoglobulininallogeneichematopoieticcelltransplantpatientsaprospectivestudyoffeasibilitysafetyandhealthcareresourceuse AT fotiosvmichelis subcutaneousimmunoglobulininallogeneichematopoieticcelltransplantpatientsaprospectivestudyoffeasibilitysafetyandhealthcareresourceuse
_version_	1718400923527544832

Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use

Ejemplares similares